Similar articles

• [Drugs for rare diseases].

  Rolfs M, Lindemalm S. Rolfs M, et al. Lakartidningen. 2010 Apr 21-27;107(16):1043. Lakartidningen. 2010. PMID: 20476696 Swedish. No abstract available.
• [Authorization and reimbursement of orphan drugs in an international comparison].

  Roll K, Stargardt T, Schreyögg J. Roll K, et al. Gesundheitswesen. 2011 Aug;73(8-9):504-14. doi: 10.1055/s-0030-1262864. Epub 2010 Sep 16. Gesundheitswesen. 2011. PMID: 20848380 Review. German.
• Limits on use of health economic assessments for rare diseases.

  Hyry HI, Stern AD, Cox TM, Roos JC. Hyry HI, et al. QJM. 2014 Mar;107(3):241-5. doi: 10.1093/qjmed/hcu016. Epub 2014 Jan 22. QJM. 2014. PMID: 24453281
• Orphan drugs and the NHS: should we value rarity?

  McCabe C, Claxton K, Tsuchiya A. McCabe C, et al. BMJ. 2005 Oct 29;331(7523):1016-9. doi: 10.1136/bmj.331.7523.1016. BMJ. 2005. PMID: 16254305 Free PMC article. Review.
• How can the risk that orphan drugs present to budgets be managed better?

  O'Neill C. O'Neill C. Clin Ther. 2010 Aug;32(9):1640-1. doi: 10.1016/j.clinthera.2010.08.007. Clin Ther. 2010. PMID: 20974321 No abstract available.